In this peer‑reviewed Cytotherapy publication, Eytan Abraham, PhD, CCO and CTO of Minaris, co‑authors a critical examination of how CAR‑T manufacturing must transform to meet the realities of scale, cost pressure, and global demand. As autologous cell therapies move from clinical innovation to commercial expectation, sponsors must rethink centralized and decentralized manufacturing models, automation strategies, … Continued